Neurocrine Biosciences CEO Kevin Gorman's 2021 pay rises 1% to $14M
Neurocrine Biosciences reports 2021 executive compensation
By ExecPay News
Published: April 7, 2022
Neurocrine Biosciences reported fiscal year 2021 executive compensation information on April 7, 2022.
In 2021, five executives at Neurocrine Biosciences received on average a compensation package of $8M, which is about the same as previous year.
Average pay of disclosed executives at Neurocrine Biosciences
Kevin C. Gorman, Chief Executive Officer, received $14M in total, which increased by 1% compared to 2020. 45% of Gorman's compensation, or $6.4M, was in stock awards. Gorman also received $701K in bonus, $6.1M in option awards, $825K in salary, as well as $55K in other compensation.
For fiscal year 2021, the median employee pay was $276,598 at Neurocrine Biosciences. Therefore, the ratio of Kevin C. Gorman's pay to the median employee pay was 51 to one.
Jude Onyia, Chief Scientific Officer, received a compensation package of $7.6M. 59% of the compensation package, or $4.5M, was in option awards.
Eiry W. Roberts, Chief Medical Officer, earned $6.4M in 2021, a 10% increase compared to previous year.
Matthew C. Abernethy, Chief Financial Officer, received $5.9M in 2021, which decreases by 6% compared to 2020.
Eric Benevich, Chief Commercial Officer, earned $5.8M in 2021, a 14% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on April 7, 2022.